Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

8.07USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$8.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
395,333
52-wk High
$9.07
52-wk Low
$2.78

Chart for

About

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $594.49
Shares Outstanding(Mil.): 73.39
Dividend: --
Yield (%): --

Financials

  VSTM.OQ Industry Sector
P/E (TTM): -- 213.33 32.89
EPS (TTM): -1.83 -- --
ROI: -130.12 -3.69 13.14
ROE: -153.19 -5.73 15.15

BRIEF-Verastem Oncology Announces Public Offering Of 7.78 Mln Common Shares Priced At $4.50per Share

* VERASTEM ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

May 16 2018

BRIEF-Verastem Oncology Announces Public Offering Of Common Stock

* VERASTEM ONCOLOGY ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

May 15 2018

BRIEF-Verastem Oncology Reports Q1 Loss Per Share Of $0.41

* VERASTEM ONCOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 03 2018

BRIEF-Verastem Reports Year-End 2017 Financial Results

* VERASTEM - EXPECTS TO HAVE SUFFICIENT CASH, CASH EQUIVALENTS AND INVESTMENTS TO FUND CURRENT OPERATING PLAN AND CAPEX REQUIREMENTS INTO H2 2018 Source text for Eikon: Further company coverage:

Mar 13 2018

BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib

* VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA

Feb 07 2018

BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL

Jan 26 2018

Earnings vs. Estimates